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Measured Variable +/- SD Result
Min/Max Lumen Diameter (>0.7) 0.61 (0.13) 21/58 (>0.7) ¼ 36%
Total Plaque Length (Pre-PCI - PB>40%) 31.63 (12.11)
Stented Length on IVUS (mm) 20.86 (6.15)
Residual Plaque Length (PB>40%) 14.60 (11.56)
Minimum Stent Area Achieved (mm2)
(>5.5)
6.79 (2.43) 38/58 (>5.5) ¼65.5%
Max Stent Area Achievable (mm2) 8.87 (2.68)
Calculated Under-deployment Area
(mm2)
2.08 (1.87)
Average Reference Vessel Lumen Area
(mm2)
10.58 (2.51)
MLA/Av Ref Vessel Lumen Area (should
be >0.8) (mm2)
0.66 (0.24) 23/58 ¼ 40%
Frequency of Longitudinal Miss 25/58 ¼ 43%
Frequency of “unstable” VH-TCFA in
residual plaque
9/58 ¼ 15.5%
Visual Frequency of Edge Dissection 5/58 ¼ 8.6%
Visual Frequency of Incomplete Stent
Apposition
13/58 ¼ 22.4%
Frequency of plaque prolapse/in-stent
issue
3/58 ¼5.2%
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Enlargement of Distal Vessel Diameter after Percutaneous Coronary
Intervention of Chronic Total Occlusion – Relationship with Collateral Flow and
Intravascular Ultrasound Findings
Yuji Nishimoto1, Koshi Matsuo1, Ryuta Sugihara1, Yasunori Ueda1
1Osaka Police Hospital, Osaka, Japan
Background: Although the vessel diameter distal to the recanalized CTO lesion is
often smaller than expected immediately after recanalization, the vessel tends to
increase their diameter after one year. Therefore, we assessed how the distal segment
vessel diameter would increase at 1-year follow-up.
Methods: Consecutive patients (n¼88) who received successfully recanalization of
CTO lesions from July 2007 to September 2011 and had 1-year follow-up catheter-
ization were analyzed. We classiﬁed them into two groups by the Rentrop collateral
ﬂow grade: Group A, grade 0 to 2 and Group B, grade 3. We evaluated by IVUS the
plaque burden and minimum lumen diameter of the distal vessel segment immediately
after recanalization. Vessel diameter distal to the recanalized CTO lesions (at 10mm
from distal stent edge) was compared between follow-up and immediately after
recanalization (baseline) by quantitative coronary angiography.
Results: Vessel diameter increased signiﬁcantly from baseline to follow-up
(2.00.7mm vs. 2.40.7mm, P<0.05). Vessel diameter increased more in Group B
than in Group A (76.9% vs. 94.3%mm P<0.05). There was no signiﬁcant difference
in IVUS ﬁndings between the patients with and without vessel diameter increase.
Conclusions: Vessel diameter in the distal segment of CTO lesion increased at 1-year
follow-up especially in the patients with good collateral ﬂow.
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Background: DESolve is a novel PLLA-based bioresorbable scaffold (BRS), coated
with a bioresorbable polylactide-based polymer that carries and delivers novolimus (5
mg/mm scaffold length). DESolve is designed to provide temporary vessel support
along with neointimal suppression, followed by full bioresorption between 1-2 years.
The aim of this study is to present the ﬁrst morphometric changes of the DESolve BRS
up to six through serial evaluation by intravascular OCT.
Methods: The DESolve NX study enrolled 126 pts with de novo coronary lesions
treated with a single scaffold available in three diameters (3.0, 3.25 and 3.5 mm) and
two lengths (14 and 18 mm). The ﬁrst 40 enrolled pts were part of an invasive imaging
sub study with IVUS and OCT, which consisted of paired analysis of automated
pullbacks performed at the end of the index procedure (baseline) and at 6 months. All
OCT images were analyzed by an independent core laboratory.
Results: 38/40 (95%) patients had serial images of adequate quality for analysis.
Adequate scaffold expansion (96.1811.83%) was obtained upon deployment. A
signiﬁcant increase in scaffold area (D: 16.93  12.90 %, p<0.0001) compensated the
small amount of NIH (0.700.26 mm2) that accrued on top of the struts over time,
resulting in only 11.274.19% scaffold obstruction, and preservation of the “unob-
structed” effective (excluding the inter-strut space) lumen (D: 4.2314.37 %,
p<0.0001). Incomplete scaffold apposition (ISA) was seen in 15 pts (39.5%) at
baseline, and persisted in 5 pts (13.2%) at 6 months. There was no late acquired ISA.
A total of 29,154 struts were analyzed (14,893 at baseline; 14,261 at follow-up). 6-
Month rate of covered struts per patient was 98.791.69%. NIH thickness on top of
the struts measured 100.5330.58 mm.
Conclusions: The DESolve BRS tolerated very good expansion upon deployment.
Signiﬁcant scaffold expansion, along with low NIH formation, generated a very low
percent scaffold obstruction and preservation of the “unobstructed” lumen,B182 JACC Vol 62/18/Suppl B j October 27–Novecontributing to an elevated efﬁcacy proﬁle. A high safety proﬁle was additionally
conﬁrmed by the elevated rates of strut coverage and absence of late acquired ISA.
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Background: Angiographically-guided stent deployment is the conventional, albeit
imperfect, approach in the setting of "real world" Percutaneous Coronary Intervention
(PCI). Recently, the ADAPT-DES study and a large meta-analysis have suggested
there may be a beneﬁt to both clinical outcomes and major adverse cardiac events
(MACE) with Intravascular Ultrasound (IVUS) guided PCI.
Methods: This was a single centre, operator blinded observational study. Patients with
a conﬁrmed troponin positive ACS were recruited. Pre-PCI the lesion was examined
with motorized IVUS and Virtual Histology (VH) (VOLCANO CORP). The operator
was blinded to the IVUS screen and carried out the procedure angiographically.
Following deployment of the stent and post-dilatation, a ﬁnal IVUS pullback was
performed. All IVUS images were processed off-line by an independent experienced
operator.
Results: The main results of the study are displayed in Table 1. 58 culprit ACS
plaques underwent full examination with IVUS-VH pre and post PCI.In particular we
found that the minimum stent area achieved was 6.79mm2 (+/-2.43), with only 65.5%
of stents achieving an MLA of >5.5mm2. The maximum stent area achievable for
stent used would have been 8.87mm2 (+/-2.68), suggesting an under-deployment area
of around 2.08mm2(+/-1.87). The average reference vessel lumen area was 10.58mm2
(+/-2.51) suggesting that stents were also under-sized. Only 36% of stents met MUSIC
criteria for stent symmetry (min/max lumen diameter>70%). Only 40% met
a deployment criteria of (MLA/av vessel lumen ares >80%).
Conclusions: We have shown that in ACS PCI, operators consistently undersize the
vessel and stent. Moreover, inadequate stent deployment, under-expansion, in-appo-
sition and geographic miss occurs frequently. This may have implications for long
term event rates, in keeping with the results of ADAPT-DES. The use of up-front
IVUS should be considered in PCI for ACS.mber 1, 2013 j TCT Abstracts/POSTER/Intravascular Imaging and PCI
